HRP20211015T1 - Cjepivo protiv citomegalovirusa (cmv) - Google Patents
Cjepivo protiv citomegalovirusa (cmv) Download PDFInfo
- Publication number
- HRP20211015T1 HRP20211015T1 HRP20211015TT HRP20211015T HRP20211015T1 HR P20211015 T1 HRP20211015 T1 HR P20211015T1 HR P20211015T T HRP20211015T T HR P20211015TT HR P20211015 T HRP20211015 T HR P20211015T HR P20211015 T1 HRP20211015 T1 HR P20211015T1
- Authority
- HR
- Croatia
- Prior art keywords
- viral vector
- seq
- glycoprotein
- amino acid
- acid sequence
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 6
- 239000013603 viral vector Substances 0.000 claims 35
- 102000003886 Glycoproteins Human genes 0.000 claims 17
- 108090000288 Glycoproteins Proteins 0.000 claims 17
- 241000701022 Cytomegalovirus Species 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 241000712891 Arenavirus Species 0.000 claims 8
- 101710186352 Probable membrane antigen 3 Proteins 0.000 claims 8
- 101710181078 Probable membrane antigen 75 Proteins 0.000 claims 8
- 101710178472 Tegument protein Proteins 0.000 claims 8
- 230000001086 cytosolic effect Effects 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 230000000890 antigenic effect Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 5
- 230000037430 deletion Effects 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002458 infectious effect Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000272186 Falco columbarius Species 0.000 claims 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 206010010430 Congenital cytomegalovirus infection Diseases 0.000 claims 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 230000005923 long-lasting effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (25)
1. Zarazni virusni vektor arenavirusa s nedostatkom replikacije konstruiran da sadrži genom sa sposobnošću pojačavanja i ekspresije svoje genetske informacije u zaraženim stanicama, pri čemu virusni vektor može stvoriti zarazne viruse potomke u stanicama koje komplementiraju, ali ne mogu stvoriti daljnje zarazne čestice potomstva u nekomplementirajućim stanicama, u kojima se uklanja otvoren okvir za čitanje arenavirusa koji kodira GP protein unutar S segmenta i zamjenjuje s:
a. nukleotidnom sekvencom koja kodira citomegalovirus glikoprotein gB, pri čemu glikoprotein gB ima deleciju citoplazmatske domene i / ili transmembranske domene; ili
b. nukleotidnom sekvencom koja kodira protein tegumenta citomegalovirusa pp65 ili njegov antigeni fragment.
2. Virusni vektor iz zahtjeva 1, naznačen time što je nukleotidna sekvenca nukleotidna sekvenca koja kodira citomegalovirus glikoprotein gB, pri čemu glikoprotein gB ima deleciju citoplazmatske domene i / ili transmembranske domene.
3. Virusni vektor iz zahtjeva 2, naznačen time što glikoprotein gB sadrži aminokiselinsku sekvencu koja je najmanje 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98%, 99% ili 100% identična aminokiselinama 1 do 771 iz SEQ ID NO: 3, a obuhvaća deleciju citoplazmatske domene
između aminokiselina 772 do 906 iz SEQ ID NO: 3.
4. Virusni vektor iz zahtjeva 2, naznačen time što glikoprotein gB sadrži aminokiselinsku sekvencu koja je najmanje 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98%, 99% ili 100% identična aminokiselinama 1 do 772 iz SEQ ID NO: 60, a obuhvaća deleciju citoplazmatske domene
između aminokiselina 773 do 907 iz SEQ ID NO: 60.
5. Virusni vektor iz zahtjeva 2, naznačen time što glikoprotein gB sadrži aminokiselinsku sekvencu koja je najmanje 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% , 98%, 99% ili 100% identična SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18 ili SEQ ID NO: 63.
6. Virusni vektor iz zahtjeva 2, naznačen time što glikoprotein gB sadrži aminokiselinsku sekvencu koja je najmanje 90%, najmanje 95% ili najmanje 98% identična SEQ ID NO: 18.
7. Virusni vektor iz zahtjeva 2, naznačen time što glikoprotein gB sadrži aminokiselinsku sekvencu koja je 100% identična SEQ ID NO: 18.
8. Virusni vektor iz zahtjeva 2, naznačen time što se glikoprotein gB sastoji od aminokiselinske sekvence koja je 100% identična SEQ ID NO: 18.
9. Virusni vektor iz zahtjeva 2, naznačen time što nukleotidna sekvenca kodira glikoprotein gB pri čemu: (i) citoplazmatska domena glikoproteina gB se briše; (ii) transmembranska domena glikoproteina gB se briše; ili (iii) brišu se citoplazmatska domena i transmembranska domena glikoproteina gB.
10. Virusni vektor iz zahtjeva 1, naznačen time što je nukleotidna sekvenca nukleotidna sekvenca koja kodira protein tegumenta citomegalovirusa pp65 ili njegov antigeni fragment.
11. Virusni vektor iz zahtjeva 10, naznačen time što tegumentni protein pp65 ili njegov antigeni fragment sadrži aminokiselinsku sekvencu koja je najmanje 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94% , 95%, 96%, 97%, 98%, 99% ili 100% identična SEQ ID NO: 36.
12. Virusni vektor iz zahtjeva 10, naznačen time što tegumentni protein pp65 ili njegov antigeni fragment sadrži aminokiselinsku sekvencu koja je najmanje 90%, najmanje 95% ili najmanje 98% identična SEQ ID NO: 36.
13. Virusni vektor iz zahtjeva 10, naznačen time što tegumentni protein pp65 ili njegov antigeni fragment sadrži aminokiselinsku sekvencu koja je 100% identična SEQ ID NO: 36.
14. Virusni vektor iz zahtjeva 10, naznačen time što se tegumentni protein pp65 sastoji od aminokiselinske sekvence koja je 100% identična SEQ ID NO: 36.
15. Virusni vektor iz bilo kojeg od prethodnih zahtjeva, naznačen time što:
(i) arenavirus je virus limfocitnog koriomeningitisa;
(ii) genomske informacije koje kodiraju virusni vektor zaraznog arenavirusa s nedostatkom replikacije potječu iz soja Klon 13 virusa limfocitnog koriomeningitisa;
(iii) virusni vektor inducira dugotrajni imunološki odgovor protiv citomegalovirusnog (CMV) glikoproteina gB ili antigena tegumentnog proteina pp65 kodiranog nukleotidnom sekvencom; ili
(iv) virusni vektor je prikladan za zaštitu od urođene CMV infekcije.
16. Sastav koji sadrži prvi virusni vektor i drugi virusni vektor, naznačen time što navedeni prvi virusni vektor i navedeni drugi virusni vektor su virusni vektor prema zahtjevu 1, i pri čemu su navedeni prvi i drugi virusni vektori različiti.
17. Sastav prema zahtjevu 16, naznačen time što navedeni prvi virusni vektor sadrži virusni vektor prema bilo kojem od zahtjeva 2-9 i pri čemu navedeni drugi virusni vektor sadrži virusni vektor iz bilo kojeg od zahtjeva 10-14.
18. Farmaceutski ili imunogeni sastav ili cjepivo koji sadrže virusni vektor prema bilo kojem od zahtjeva 1 do 15, ili sastav prema zahtjevu 16 ili 17, i farmaceutski prihvatljiv nosač.
19. Cjepivo prema zahtjevu 18, koje sadrži gB protein humanog citomegalovirusa (HCMV), naznačeno time što se citoplazmatska domena HCMV gB briše, a pri čemu HCMV gB protein:
(i) sadrži N-terminalne 772 aminokiseline gB CMV soja Merlin (SEQ ID NO: 60), ali ne sadrži sadrže preostale C-terminalne aminokiseline gB CMV soja Merlin;
(ii) se sastoji uglavnom od N-terminalnih 772 aminokiselina gB CMV soja Merlin (SEQ ID NO: 60);
(iii) sastoji se uglavnom od N-terminalnih 772 aminokiselina gB CMV soja Merlin (SEQ ID NO: 60) nakon čega slijedi ostatak arginina na položaju 773; ili
(iv) sadrži aminokiselinsku sekvencu koja je najmanje 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, najmanje 99,5% ili 100% identična aminokiselinskoj sekvenci SEQ ID NO: 18.
20. Virusni vektor iz bilo kojeg od zahtjeva 1 do 15, ili sastav iz zahtjeva 16 ili 17, ili farmaceutski ili imunogeni sastav ili cjepivo prema zahtjevu 18 ili 19, naznačeni time što navedeni virusni vektor, navedeni sastav, navedeni farmaceutski ili imunogeni sastav, ili navedeno cjepivo je pogodno za intramuskularnu injekciju.
21. Virusni vektor iz bilo kojeg od zahtjeva 1 do 15 i 20, ili sastav iz zahtjeva 16, 17 i 20, ili farmaceutski ili imunogeni sastav ili cjepivo prema bilo kojem od zahtjeva 18 do 20, za uporabu u metodi liječenja ili prevencije infekcije citomegalovirusom u pacijenta.
22. Izolirana nukleinska kiselina, pri čemu nukleinska kiselina kodira genomski S segment arenavirusa u kojem je otvoreni okvir za čitanje koji kodira GP protein unutar genomskog S segmenta arenavirusa uklonjen i zamijenjen s:
a. nukleotidnom sekvencom koja kodira citomegalovirus glikoprotein gB, pri čemu glikoprotein gB ima deleciju citoplazmatske domene i / ili transmembranske domene; ili
b. nukleotidnom sekvencom koja kodira protein tegumenta citomegalovirusa pp65 ili njegov antigeni fragment.
23. Ekspresijski vektor koji sadrži izoliranu nukleinsku kiselinu prema zahtjevu 22.
24. Stanica koja sadrži izoliranu nukleinsku kiselinu prema zahtjevu 22 ili ekspresijski vektor prema zahtjevu 23.
25. Postupak za stvaranje zaraznog virusnog vektora arenavirusa s nedostatkom replikacije, koji sadrži:
a. transfekciju u stanicu domaćina nukleinske kiseline prema zahtjevu 22 ili ekspresijskog vektora prema zahtjevu 23;
b. održavanje stanice domaćina u uvjetima pogodnim za stvaranje virusa; i
c. berbu zaraženog virusnog vektora arenavirusa s nedostatkom replikacije;
pri čemu stanica domaćin izražava otvoreni okvir za čitanje koji kodira GP protein.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
| EP14820762.4A EP3077519B1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211015T1 true HRP20211015T1 (hr) | 2021-10-01 |
Family
ID=52232138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211015TT HRP20211015T1 (hr) | 2013-12-03 | 2021-06-28 | Cjepivo protiv citomegalovirusa (cmv) |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (hr) |
| EP (2) | EP3904522A1 (hr) |
| JP (2) | JP6818551B2 (hr) |
| CN (2) | CN105980570B (hr) |
| AU (2) | AU2014359276B2 (hr) |
| CA (1) | CA2932318C (hr) |
| CY (1) | CY1124288T1 (hr) |
| DK (1) | DK3077519T3 (hr) |
| ES (1) | ES2868427T3 (hr) |
| HK (1) | HK1226440A1 (hr) |
| HR (1) | HRP20211015T1 (hr) |
| HU (1) | HUE054579T2 (hr) |
| LT (1) | LT3077519T (hr) |
| PL (1) | PL3077519T3 (hr) |
| PT (1) | PT3077519T (hr) |
| RS (1) | RS61993B1 (hr) |
| SI (1) | SI3077519T1 (hr) |
| WO (1) | WO2015082570A1 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| SI3218504T1 (sl) | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| DK3371316T3 (da) * | 2015-11-04 | 2023-01-23 | Hookipa Biotech Gmbh | Vacciner mod hepatitis b-virus |
| LT3373959T (lt) * | 2015-11-12 | 2022-07-25 | Hookipa Biotech Gmbh | Arenavirusų dalelės, kaip vėžio vakcinos |
| US11260090B2 (en) | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| IL269892B2 (en) | 2017-04-14 | 2024-04-01 | Regenxbio Inc | Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| WO2019216929A1 (en) * | 2018-05-11 | 2019-11-14 | City Of Hope | Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof |
| CA3116175A1 (en) * | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| WO2020121983A1 (ja) * | 2018-12-10 | 2020-06-18 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| JP2023500928A (ja) | 2019-11-07 | 2023-01-11 | ユニベルシタト バーゼル | ベクターとしてのアレナウイルス |
| EP4163378A4 (en) * | 2020-06-09 | 2024-03-13 | KM Biologics Co., Ltd. | PENTAMER AND GB FUSION PROTEIN OF CYTOMEGALOVIRUS AND VACCINE CONTAINING THIS FUSION PROTEIN |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| EP4291249A2 (en) | 2021-02-10 | 2023-12-20 | RegenxBio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| WO1989007143A1 (en) * | 1988-01-29 | 1989-08-10 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP1265916B1 (en) * | 2000-03-21 | 2005-12-21 | Genzyme Corporation | Therapeutic anti-cytomegalovirus compounds |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| US8486420B2 (en) * | 2005-02-15 | 2013-07-16 | The University Of North Carolina At Chapel Hill | Live virus vaccines |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| EP4186978A1 (en) * | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| EP2471553A4 (en) * | 2009-06-26 | 2013-08-28 | Vectorite Biomedica Inc | IMMUNOGENIC COMPOSITION WITH PEPTIDES FROM CYTOMEGALOVIRUS AND THEIR USE |
| CA2813522C (en) | 2010-10-15 | 2022-06-21 | Guy Jean Marie Fernand Pierre Baudoux | Cytomegalovirus gb polypeptide antigens and uses thereof |
| WO2012093340A2 (en) * | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| CN104853771A (zh) * | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 巨细胞病毒蛋白的复合物 |
| WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
| SI3218504T1 (sl) * | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| DK3371316T3 (da) | 2015-11-04 | 2023-01-23 | Hookipa Biotech Gmbh | Vacciner mod hepatitis b-virus |
| LT3373959T (lt) | 2015-11-12 | 2022-07-25 | Hookipa Biotech Gmbh | Arenavirusų dalelės, kaip vėžio vakcinos |
| IL262963B1 (en) | 2016-05-18 | 2024-09-01 | Hookipa Biotech Gmbh | Three-segmented PICHINDE viruses as vaccine vectors |
| US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
| JP2023500928A (ja) | 2019-11-07 | 2023-01-11 | ユニベルシタト バーゼル | ベクターとしてのアレナウイルス |
| CR20220602A (es) | 2020-05-29 | 2023-05-16 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus |
-
2014
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en active Application Filing
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
-
2016
- 2016-12-23 HK HK16114631A patent/HK1226440A1/zh unknown
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en active Pending
- 2021-06-28 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3077519B1 (en) | 2021-03-31 |
| AU2021202541A1 (en) | 2021-05-27 |
| WO2015082570A1 (en) | 2015-06-11 |
| CN115058452A (zh) | 2022-09-16 |
| RS61993B1 (sr) | 2021-07-30 |
| EP3077519A1 (en) | 2016-10-12 |
| US10111945B2 (en) | 2018-10-30 |
| ES2868427T3 (es) | 2021-10-21 |
| CN105980570B (zh) | 2022-06-07 |
| US20230181725A1 (en) | 2023-06-15 |
| HK1226440A1 (zh) | 2017-09-29 |
| JP2021061848A (ja) | 2021-04-22 |
| CA2932318A1 (en) | 2015-06-11 |
| SI3077519T1 (sl) | 2021-07-30 |
| PT3077519T (pt) | 2021-05-13 |
| HUE054579T2 (hu) | 2021-09-28 |
| PL3077519T3 (pl) | 2021-10-18 |
| WO2015082570A8 (en) | 2015-11-26 |
| JP7001807B2 (ja) | 2022-02-04 |
| JP6818551B2 (ja) | 2021-01-20 |
| AU2014359276B2 (en) | 2021-01-28 |
| CA2932318C (en) | 2023-10-10 |
| US11554169B2 (en) | 2023-01-17 |
| CN105980570A (zh) | 2016-09-28 |
| LT3077519T (lt) | 2021-04-26 |
| DK3077519T3 (en) | 2021-06-14 |
| JP2017503482A (ja) | 2017-02-02 |
| AU2014359276A1 (en) | 2016-06-16 |
| EP3904522A1 (en) | 2021-11-03 |
| CY1124288T1 (el) | 2022-07-22 |
| US20190247493A1 (en) | 2019-08-15 |
| US20160296619A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2017503482A5 (hr) | ||
| JP2021061848A5 (hr) | ||
| Vander Veen et al. | Alphavirus replicon vaccines | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| Rühl et al. | Vaccination against the Epstein–Barr virus | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| HRP20201684T1 (hr) | Tri-segmentirani arenavirusi kao vektori cjepiva | |
| JP2021182922A5 (hr) | ||
| Liniger et al. | Use of viral vectors for the development of vaccines | |
| Murrell et al. | Genetic stability of bacterial artificial chromosome-derived human cytomegalovirus during culture in vitro | |
| Wang | Nonhuman primate models for Epstein-Barr virus infection | |
| CN1989250B (zh) | Tc-83衍生的甲病毒属载体、颗粒和方法 | |
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| Brennan et al. | Mapping of transcription termination within the S segment of SFTS phlebovirus facilitated generation of NSs deletant viruses | |
| JP2017510262A5 (hr) | ||
| CN113930452B (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| Morimoto et al. | Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity | |
| AU2019374480A1 (en) | Compositions and methods | |
| Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
| Hidmark et al. | Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling | |
| Kim et al. | Generation of G gene-deleted viral hemorrhagic septicemia virus (VHSV) and evaluation of its vaccine potential in olive flounder (Paralichthys olivaceus) | |
| Jindra et al. | Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach | |
| Zhang et al. | A novel inactivated bivalent vaccine for chickens against emerging hepatitis-hydropericardium syndrome and infectious bursal disease | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 |